Top ranking comes alongside recent acknowledgements from S&P Global, CDP and EcoVadis, reflecting Beko's commitment to sustainability, innovation and advanced manufacturing
ISTANBUL, Jan. 26, 2026 /PRNewswire/ -- Beko, a global leader in home appliances, has been recognised in the 2026 Corporate Knights Global 100, ranking 45th among the world's most sustainable publicly listed companies and first globally in the household durables industry. Following a category leading ranking in the 2025 Corporate Knights Global 100, where Beko placed 68th overall, the company advanced 23 positions in 2026 while maintaining its #1 position in the household durables industry. This achievement reflects Beko's continued progress in developing sustainability as a core driver of its strategy, operations and sustained growth.
The Corporate Knights recognition builds on a series of recent global sustainability assessments that consistently position Beko among industry leaders. In 2025, Beko was named one of TIME Magazine's World's Most Sustainable Companies for the second-year running, earning a place in the Top 20 and securing the #1 position in its industry. Furthermore, the company achieved the highest score in the S&P Global Corporate Sustainability Assessment (CSA) within the DHP Household Durables Industry for the seventh consecutive year, was awarded a Gold Medal in the EcoVadis Sustainability Assessment, placing it in the top 3% of all companies assessed. In 2026, Beko once again achieved "Double A" status from the Carbon Disclosure Project (CDP) for both Climate Change and Water Security, placing the company among the global leaders in corporate transparency.
Turning Commitment into Action
These achievements recognise the importance Beko places on sustainability and real climate action. In 2024, the company invested 165 million Euros in environmental-related investments and expenditures. Today, low-carbon products generate for more than 70% of total revenue, while energy-efficient appliances continue to make up a significant portion of this share. Material efficiency initiatives embedded in product design delivered savings of more than 17,000 tonnes. Circularity is further strengthened through the use of over 27,800 tonnes of recycled plastics across manufacturing in 2024. In parallel, Beko scaled up its refurbishment activities, extending the life of more than 114,000 appliances in 2024 through its global refurbishment network.
"Our recognition in the Corporate Knights Global 100, alongside our leadership rankings from S&P Global, CDP, and EcoVadis, confirms that sustainability sits at the core of how we design, invest, and grow our business across the markets we operate. Together, these outcomes validate our commitment and prove that scale and innovation, when guided by responsibility, can deliver measurable impact for society, the economy, and our planet." said Hakan Bulgurlu, CEO of Beko.
The Corporate Knights Global 100 is widely regarded as one of the most rigorous global sustainability rankings. The index assesses how effectively public-listed companies are developing sustainable economic models, focusing on sustainable revenue, investment, and growth, with ESG performance serving as a minimum threshold. Beko's performance highlights its ability to scale sustainability across products, manufacturing and capital allocation, while delivering resilient business outcomes.
About Beko
Beko is an international home appliance company with a strong global presence, operating through subsidiaries in more than 55 countries with a workforce of over 50,000 employees and production facilities spanning multiple regions—including Europe, Asia, Africa, and the Middle East. Beko has 22 brands owned or used with a limited license (Arçelik, Beko, Whirlpool*, Grundig, Hotpoint, Arctic, Ariston*, Leisure, Indesit, Blomberg, Defy, Dawlance, Hitachi*, Voltas Beko, Singer*, ElektraBregenz, Flavel, Bauknecht, Privileg, Altus, Ignis, Polar). Beko became the largest white goods company in Europe with its market share (based on volumes) and reached a consolidated turnover of 10.6 billion Euros in 2024. Beko's 28 R&D and Design Centers & Offices across the globe are home to over 2,300 researchers and hold more than 4,500 international registered patent applications to date. The company has achieved the highest score in the S&P Global Corporate Sustainability Assessment (CSA) in the DHP Household Durables industry for the seventh consecutive year (based on the results dated 16 October 2025).** The company has been recognized as the 17th most sustainable company on TIME Magazine and Statista's 2025 list of the World's Most Sustainable Companies. Beko's vision is 'Respecting the World, Respected Worldwide.'
www.bekocorporate.com
*Licensee limited to certain jurisdictions.
**The data presented belongs to Arçelik A.Ş., a parent company of Beko.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Beko Secures #1 Spot for Household Durables Industry in the Corporate Knights Global 100
Beko Secures #1 Spot for Household Durables Industry in the Corporate Knights Global 100
SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, jointly announced today the signing of a strategic collaboration agreement on the development and manufacturing of multiple next-generation bi-/multi-functional fusion programs from HanchorBio's pipeline.
Under the agreement, WuXi Biologics will provide integrated, end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing. The collaboration is designed to enhance CMC execution efficiency, accelerate clinical translation, and support scalable global development and manufacturing of HanchorBio's innovative fusion protein portfolio derived from its Fc-Based Designer Biologics (FBDB™) platform.
This partnership reflects HanchorBio's strategy to advance its platform-derived, multi-asset pipelines with development speed, manufacturing robustness, and capital efficiency from early clinical stages through commercialization. By leveraging WuXi Biologics' proven capabilities in complex biologics and its global quality systems, HanchorBio aims to shorten development timelines and maintain flexibility across multiple clinical programs.
WuXi Biologics brings extensive experience in complex modalities, including bispecific and multi-specific antibodies, antibody-drug conjugates (ADCs), and fusion proteins. As of 2025, there are 945 projects on WuXi Biologics' integrated platform, with approximately 60% are bi- and multi-specific antibodies, ADCs and fusion proteins, underscoring its track record in enabling accelerated development and manufacturing of advanced therapeutic modalities. Its proprietary technology platforms, such as WuXia™ TrueSite - targeted integration (TI)-based CHO cell line platform, and WuXiHighTM - high-throughput formulation development platform, are designed to enhance speed, quality, and scalability.
For HanchorBio, the collaboration supports continued expansion of its proprietary FBDB™ technology platform, which enables the rational design of multi-functional fusion proteins intended to modulate both innate and adaptive immunity. The partnership represents a significant step in aligning discovery innovation with industrial-scale and globally compliant execution as HanchorBio advances its oncology and autoimmune pipelines toward global clinical development.
Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, said: " We are excited to embark on this collaboration with HanchorBio, which underscores the strong trust they placed in WuXi Biologics' comprehensive, end-to-end capabilities for developing next-generation biologics, especially complex molecules. By leveraging our industry-leading technology platforms, proven expertise, and unwavering commitment to quality, we strive to accelerate the development of HanchorBio's innovative bi-/multi-fusion proteins and help bring transformative therapies to patients worldwide."
Dr. Scott Liu, Founder, Chairman, and Chief Executive Officer of HanchorBio, commented: "This partnership with WuXi Biologics strengthens our ability to translate platform-driven innovation into high-quality clinical and commercial assets. As we advance multiple next-generation fusion protein programs, execution speed, manufacturing reliability, and scalability are critical. WuXi Biologics' proven expertise in complex biologics and global development makes them a strong strategic partner as we build a differentiated, multi-asset immunotherapy pipeline."
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany, Singapore and Qatar, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
Contacts
Media
PR@wuxibiologics.com
Business
info@wuxibiologics.com
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TPEx: 7827) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio's proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities, aiming to activate both innate and adaptive immune pathways to overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies. For more information, please visit: https://www.HanchorBio.com
Contacts
IRPR@hanchorbio.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline
